Overview
- 8 inspections across 8 sites are on record.
- 17 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-05-07.
At a glance
Inspections
8
Sites
8
Observations
17
Career since
Feb 2025
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Fisher Clinical Services, Inc. | 7 May 2026 | Human Drugs | |
| Granules Pharmaceuticals Inc. | 3 Apr 2026 | Human Drugs | View 483 → |
| Aphena Pharma Solutions - Maryland, LLC | 20 Feb 2026 | Human Drugs | View 483 → |
| FairyGene, Inc. | 15 Jan 2026 | Human Drugs | View 483 → |
| SigmaPharm Laboratories LLC | 17 Dec 2025 | Human Drugs | View 483 → |
Sites inspected
Fisher Clinical Services, Inc.Allentown, United States1 insp.
Granules Pharmaceuticals Inc.Chantilly, United States1 insp.
Aphena Pharma Solutions - Maryland, LLCEaston, United States1 insp.
FairyGene, Inc.Bristol, United States1 insp.
SigmaPharm Laboratories LLCBensalem, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
David A Oluwo2 shared
Karen A Briggs2 shared
Christina K Theodorou1 shared
Lu Chen1 shared
Azeezat M Lawal1 shared
Catherine O Lamptey1 shared
Pushpa S Jayasekara1 shared
Full investigator report
Get the verbatim findings behind Ofuje D Daniyan's 17 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site